Mineralys Therapeutics, Inc.
MLYS
$27.38
$0.110.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 19.49% | 13.02% | -11.82% | -59.41% | -107.62% |
| Total Depreciation and Amortization | 0.00% | 37.21% | 117.86% | 235.29% | 525.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 80.88% | 389.12% | 2,240.00% | 655.75% | 340.36% |
| Change in Net Operating Assets | 172.51% | -71.32% | -140.53% | -138.56% | -271.67% |
| Cash from Operations | 29.20% | 14.37% | -33.41% | -98.04% | -120.09% |
| Capital Expenditure | 59.46% | 84.38% | 100.00% | 37.29% | 37.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -537.81% | -438.74% | -966.36% | 152.56% | 202.57% |
| Cash from Investing | -538.03% | -439.04% | -969.93% | 152.43% | 202.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 124.88% | 407.30% | 324.43% | 70.88% | 62.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 10.11% | 65.72% | 58.21% | -506.35% |
| Cash from Financing | 125.14% | 408.86% | 325.73% | 71.26% | 63.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -170.02% | -9.19% | 996.44% | 201.95% | 255.95% |